{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Junction+Adenocarcinoma&page=11", "query": { "condition": "Gastroesophageal Junction Adenocarcinoma", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 342, "total_pages": 35, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Junction+Adenocarcinoma&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastroesophageal+Junction+Adenocarcinoma&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T00:32:15.777Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05329766", "title": "A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Tract Malignancies" ], "interventions": [ { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Quemliclustat", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 332, "start_date": "2022-06-10", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-14T00:32:15.777Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Derby", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05329766" }, { "nct_id": "NCT06445972", "title": "Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastroesophageal Junction", "Gastroesophageal Adenocarcinoma", "Esophageal Neoplasms", "Esophageal Cancer" ], "interventions": [ { "name": "Ramucirumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Rescue Medications", "type": "DRUG" }, { "name": "HER3-DXd", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2024-08-07", "completion_date": "2030-08-08", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-14T00:32:15.777Z", "location_count": 8, "location_summary": "Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06445972" }, { "nct_id": "NCT04060342", "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Triple Negative Breast Cancer", "Castration-resistant Prostate Cancer", "Microsatellite Stable Colorectal Cancer", "Non-small Cell Lung Cancer", "Small-cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Urothelial Carcinoma", "Renal Cell Carcinoma", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "GB1275", "type": "DRUG" }, { "name": "nab-paclitaxel and gemcitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2019-08-13", "completion_date": "2022-04-11", "has_results": false, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-10-14T00:32:15.777Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04060342" }, { "nct_id": "NCT07631000", "title": "A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastroesophageal-junction Cancer" ], "interventions": [ { "name": "Cadonilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2026-05-27", "completion_date": "2029-05-27", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-14T00:32:15.777Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07631000" }, { "nct_id": "NCT01585987", "title": "An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Best Supportive care (BSC)", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2012-07", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-05-17", "last_synced_at": "2026-10-14T00:32:15.777Z", "location_count": 4, "location_summary": "Miami Beach, Florida • New York, New York • Houston, Texas", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01585987" }, { "nct_id": "NCT05753306", "title": "Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Metastatic Malignant Neoplasm in the Peritoneum" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gastrectomy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Hyperthermic Intraperitoneal Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 40, "start_date": "2023-04-20", "completion_date": "2030-03-25", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-10-14T00:32:15.777Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05753306" }, { "nct_id": "NCT00964080", "title": "Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "MBP-426/Leucovorin/5-FU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mebiopharm Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2009-05", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2014-12-02", "last_synced_at": "2026-10-14T00:32:15.777Z", "location_count": 3, "location_summary": "Dallas, Texas • Houston, Texas • Salt Lake City, Utah", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00964080" }, { "nct_id": "NCT05980416", "title": "Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stomach Neoplasm", "Gastrointestinal Neoplasms", "Digestive System Neoplasm", "Neoplasms by Site", "Neoplasms" ], "interventions": [ { "name": "EO-3021", "type": "DRUG" }, { "name": "Ramucirumab (CYRAMZA®)", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elevation Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2023-08-10", "completion_date": "2025-06-02", "has_results": true, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-10-14T00:32:15.777Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Duarte, California • New Haven, Connecticut + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05980416" }, { "nct_id": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1756, "start_date": "2013-01-31", "completion_date": "2019-12-16", "has_results": true, "last_update_posted_date": "2021-12-20", "last_synced_at": "2026-10-14T00:32:15.777Z", "location_count": 53, "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 45 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01772004" }, { "nct_id": "NCT00526110", "title": "Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastrointestinal Diseases" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2004-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-10-31", "last_synced_at": "2026-10-14T00:32:15.777Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00526110" } ] }